Treating acute renal failure with soluble thrombomodulin variants
AssigneesEli Lilly and Company, Indiana University Research and Technology Corporation
InventorsBrian William Grinnell, Bryan Edward Jones, Bruce A. Molitoris
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for preventing and/or treating subjects with acute renal failure caused by a variety of conditions. The method comprises administering to the subject soluble thrombomodulin which does not activate Protein C. In conjunction with standard of care, soluble thrombomodulin that does not activate Protein C will prevent or reduce acute kidney injury and subsequent morbidity and mortality.
Claims4
A soluble thrombomodulin variant consisting of the sequence SEQ ID NO:
- 10.
A method of treating acute renal failure comprising administering an effective amount of a soluble thrombomodulin variant that does not activate Protein C to a patient in need thereof wherein the soluble thrombomodulin variant consists of the sequence SEQ ID NO:
- 10.
A method of preventing acute renal failure comprising administering an effective amount of a soluble thrombomodulin variant that does not activate Protein C to a patient in need thereof wherein the soluble thrombomodulin variant consists of the sequence SEQ ID NO:
- 10.
Dependencies are inferred from the claim text.